Table 2 Clinical trials comprising patients with HCC and developing pulmonary metastases after TIPS placement
From: Risks and benefits of TIPS in HCC and other liver malignancies: a literature review
Author | Study type | Enrolled patients | Liver malignancy | Shunts traversing the tumour | Cases with pulmonary metastases post TIPS | Time between TIPS placement and diagnosis of pulmonary metastases (months) |
|---|---|---|---|---|---|---|
Tsauo J, et al. 2021 [17] | Retrospective, single-centre | 126 | HCC (n = 126) | 8 | 3, amongst them no shunt traversing the tumour | 3.9–32.9 |
Zhao H, et al. 2018 [39] | Systematic review | 280 | HCC (n = 280) | 35 | 2 | 5 and 72 |
Wallace M, et al. 2003 [67] | Case series | 9 | HCC (n = 7) Pancreatic neuroendocrine metastases (n = 1) Metastatic gastrointestinal stroma tumour (n = 1) | 9 | 2 | 5 and 10 |